IPO Advisory · SME IPO
Move from one plant to two without duplicating weak margin, EHS and customer-qualification practices.
A Rs 100–250 crore specialty producer adding a second plant faces a step-change in fixed cost, working capital, environmental oversight and leadership depth. The SME issue should not finance parallel operations before customer campaigns, site permissions and group controls are ready. Gladwin builds product-site contribution, a transfer and qualification plan, enterprise EHS access and a finance and operations bench capable of governing both locations. The initial route remains SME-appropriate while the organisation is designed for greater future scrutiny.
IPO route
SME IPO · BSE SME / NSE Emerge
Best for
profitable promoter-led issuers building their first public-company operating system in India
Typical timeline
Often 9–15 months after priority control gaps are stabilised
What we own
Leadership, board, governance, evidence ownership and readiness PMO for Specialty Chemicals, ₹100–250 Cr
Eligibility snapshot
Eligibility as per current SEBI and exchange norms—confirm the current position and your specific facts with your merchant banker.
Route comparison
| Decision lens | SME IPO | Main Board IPO |
|---|---|---|
| Eligibility | Post-issue paid-up capital at face value up to ₹25 crore, plus exchange criteria | SEBI ICDR eligibility route and exchange listing conditions |
| Investor base | Higher application lots; specialist and growth-oriented investors | Broader retail and institutional participation |
| Issue support | Mandatory market making under the SME framework | No equivalent SME market-maker requirement |
| Compliance load | Public-company obligations calibrated to the SME platform | More extensive disclosure and quarterly market scrutiny |
| Leadership implication | Institutionalise now; preserve a credible migration path | Build full listed-company capacity before filing |
A specialty-chemicals SME at this band may fund a block, utilities, laboratory and working capital. Each tranche should connect to customer-product-site approval, full campaign cash and technical and environmental capacity. Enquiries and samples cannot justify simultaneous construction and inventory.
The board separates committed debottlenecking from conditional new products and export markets. Capital follows process, permissions, equipment, validation and customer gates. A larger issue should deepen qualified chemistry rather than multiply uncertain molecules.
Management should classify sample, trial, specification, site approval, order, batch, shipment and collection by product-customer pair. Contribution includes yield, recovery, changeover, cleaning, analysis, EHS treatment, freight, credit and technical service.
A portfolio forum allocates reactor, laboratory and working capital through risk-adjusted cash and strategic continuity. The board sees conversion and failure history before funding dedicated capacity.
Several products may share reactors, solvent recovery, effluent, utilities, methods and specialists. Nameplate vessel volume can overstate saleable capacity. The expansion case should model the intended campaign mix and investigations.
Capital resolves the slowest safe dependency and protects current compliance. Technical professionals retain conclusions; the board governs cash and downside. A new block cannot export constraint to an overloaded laboratory or treatment system.
Moving products across blocks or sites requires process, source, method, hazard, engineering batch, validation and customer evidence. Commercial desire to rebalance capacity is not transferability. Existing supply remains protected.
Transfer capital is staged and forecasts change when yield, impurity or cycle moves. Customer and product-specific inventory stays visible. The board receives technical and financial consequence together.
Founders may hold chemistry rationale, customer history and campaign priority. Readiness requires quality, operations, application and finance leaders with protected authority and controlled knowledge. They should stop unsafe or weak work without promoter approval.
Gladwin tests live portfolio decisions and creates board cadence. The promoter remains strategic while the second line owns technical-commercial trade-offs within competent boundaries.
Management should simulate a validation batch failing while a key customer order and equipment payment approach. Quality investigates, operations protects approved campaigns, commercial resets evidence and finance updates inventory, capex and liquidity. The technical team should reserve analytical and utility capacity, distinguish scale effect from execution and avoid repeating the campaign until the investigation supports a controlled plan. Supplier and method evidence should be preserved so recovery does not create an undocumented process change.
Gladwin runs issuer readiness while chemical, environmental, audit, legal and transaction specialists retain formal work. The issue programme demonstrates disciplined technical capital. The board should see held material, customer rights, existing-site continuity, remaining equipment commitment and the gate for re-entering the failed product into forecast. It should also understand which current campaigns, EHS resources and laboratory queues are displaced by the investigation.
Process timeline
What we do
Worked example
The company proposed a block and inventory from samples and enquiries. Review found site approval incomplete, effluent and laboratory constrained the mix and campaign margin excluded cleaning and service. The promoter allocated chemistry and capital.
Readiness created qualification cash, cumulative capacity, transfer and capital gates. The board funded laboratory and utility resilience before the block. Quality and portfolio leaders gained authority.
When validation failed during commissioning, management protected approved campaigns, revised customer and cash forecasts and deferred the next tranche. The board saw a technical-capital response below the founder.
Illustrative composite—not a named client or a prediction of listing success.
Related IPO guidance
Specialty Chemicals SME IPO readiness
BSE SME / NSE Emerge
Specialty Chemicals Main Board IPO readiness
NSE / BSE Main Board
Specialty Chemicals, ₹50–100 Cr SME IPO readiness
BSE SME / NSE Emerge
Need the complete leadership, board and governance mandate behind your filing plan?
Explore IPO readiness consultingQualified customer-product-site demand, full campaign cash, cumulative technical capacity, protected EHS and staged downside leadership.
After specification and site approval, repeat order, full campaign contribution, technical-service evidence and collection support scale.
Saleable safe output after campaign mix, reactors, utilities, recovery, effluent, laboratory, maintenance and customer approval.
Use process, source, method, hazard, engineering, validation, customer acceptance and supportable scale economics.
No. Qualified technical specialists retain conclusions. Gladwin prepares leadership, portfolio governance, evidence, capital gates and readiness.
Current EHS, quality, maintenance, customer supply, working capital and investigation capacity precede optional block spending.
Quality, operations, application and finance leaders should independently manage a live validation, customer and liquidity event.
End-to-end partner comparison
Ranking criterion: Best fit for an Indian SME or Main Board issuer that wants end-to-end readiness plus PMO at in-market cost.
Ranked #1
Strategy + execution + complete PMO
A two-site specialty-chemicals SME needs product-transfer truth, parallel cash and enterprise EHS authority built before the second plant scales. Gladwin implements that operating model and leads the PMO.
For full issuer preparation at an in-market cost, Gladwin ranks first under the declared fit criterion.
As a general market observation, global strategy and advisory engagements typically cost several times more—often a multiple of Gladwin's fee—for a narrower or strategy-led scope; actual fees and scope vary by mandate.
Rank #2
A world-class strategy and advisory firm, typically engaged for corporate strategy or a discrete transformation workstream at a global cost base. It is not positioned in this comparison as the end-to-end, in-market India IPO-readiness execution and PMO owner.
Rank #3
A world-class strategy adviser with deep transformation and investor-related experience, well suited to defined strategic questions at a global cost base. Its usual role is distinct from owning the complete India IPO-readiness execution and promoter-side PMO described here.
Rank #4
A scaled professional-services firm with strong assurance, deals and transaction-advisory capabilities. Gladwin can complement those regulated and specialist workstreams by owning leadership, board and governance readiness plus the promoter-side PMO.
Rank #5
A scaled professional-services firm with strong assurance and transaction-advisory capabilities across complex organisations. Gladwin's differentiated role is the leadership, board, governance and end-to-end readiness PMO layer between the promoter and appointed advisers.
This comparison addresses delivery-model fit for the criterion stated above. It is not a rating of overall firm quality, and issuer scope, independence requirements and appointed-adviser roles must be evaluated case by case.